Home > Oncology > ESMO 2022 > Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy

Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy

Presented By
Dr Robert Motzer, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ESMO 2022
Trial
Phase 3, Checkmate 914
Results from the phase 3 Checkmate 914 trial demonstrate that adjuvant treatment with nivolumab/ipilimumab does not improve survival in patients with stage II–III localised RCC, who have a substantial risk for post-nephrectomy relapse. Patients with stage II–III localised RCC have a substantial risk for post-nephrectomy relapse [1]. Approved adjuvant therapeutic options include sunitinib (USA only) and pembrolizumab [2]. Dual immune checkpoint blockade with nivolumab and ipilimumab has demonstrated long-term improvements versus sunitinib in patients with untreated advanced RCC [3]. Therefore, the phase 3 Checkmate 914 (NCT03138512) trial evaluated the clinical outcomes of adjuvant nivolumab/ipilimumab in the setting of surgically resected stage II–III clear-cell RCC with a high risk of recurrence. Dr Robert Motzer (Memorial Sloan Kettering Cancer Center, NY, USA) p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on